04). During the mean follow-up of 7 months, three patients underwent drug-eluting balloon angioplasty for failure of AVF to mature due to stenosis (1 in Anlotinib ic50 the PBA group and 2 in the HD group). Six-month reintervention rate was significantly lower in the PBA group (5%) compared with the HD group (43%) (P = .02). At 6 months, primary patency rates were 95% in the PBA group and 57% in the HD group (P = .01). Working AVF rate was 100% in the PBA vs 90% in the HD group.
Conclusions: PBA of very small cephalic veins during the creation of a distal AVF for hemodialysis is a safe and feasible procedure. This technique assures excellent primary patency, maturation time,
and dramatically decreases reintervention rate. (J Vasc Surg 2013;57:131-6.)”
“Salvinorin A (SA) is a highly selective kappa opioid receptor agonist and the putative psychoactive compound in Salvia divinorum (SD), an increasingly abused hallucinogenic plant.
The objectives of this study were to characterize the physiological and subjective effects of SA versus placebo and measure drug and metabolite levels.
Sublingual SA doses up to 4 mg
were administered in dimethyl sulfoxide/polyethylene glycol 400 solution to eight SD-experienced subjects using a placebo-controlled ascending-dose design.
No dose of SA produced significantly greater physiological or subjective effects than placebo. Furthermore, effects did not resemble reported “”typical”" effects of smoked SD. SA was GW3965 research buy detectable in plasma and urine, but was, in most cases, below the reliable limit of quantification (0.5 ng/mL).
Our results suggest
that the sublingual bioavailability of SA is low. Higher doses, alternate formulations, or alternate routes of administration will A-1210477 be necessary to study the effects of SA in humans.”
“Objective: Currently, no formal practice guidelines exist regarding the use of endografts to exclude hemodialysis access pseudoaneurysms and prolong access lifespan in dialysis patients. We evaluated the efficacy of percutaneous endograft placement for exclusion of hemodialysis access pseudoaneurysms.
Methods: Between July 2005 and October 2009, 32 patients were prospectively evaluated. Twenty-four patients were actively enrolled in the study based upon clinical and ultrasonographic evaluation of their hemodialysis accesses. Self-expanding covered endografts were placed percutaneously to exclude access pseudoaneurysms. Patients were evaluated at 2 and 6 months to assess for graft patency, access or outflow stenosis, endoleak, or stent graft migration.
Results: No procedural complications resulted from these interventions. An average of 1.8 endografts was placed per patient, with patients requiring between 1 and 3 endografts to exclude pseudoaneurysms. Primary-assisted patency was 83% at completed 2-month follow-up and 54% at 6-month follow-up. At 12 months, primary-assisted patency was 50%.